Article Text

PDF
Original article
CXCL14 is a candidate biomarker for Hedgehog signalling in idiopathic pulmonary fibrosis
  1. Guiquan Jia1,
  2. Sanjay Chandriani1,
  3. Alexander R Abbas1,
  4. Daryle J DePianto1,
  5. Elsa N N'Diaye1,
  6. Murat B Yaylaoglu1,
  7. Heather M Moore1,
  8. Ivan Peng1,
  9. Jason DeVoss1,
  10. Harold R Collard2,
  11. Paul J Wolters2,
  12. Jackson G Egen1,
  13. Joseph R Arron1
  1. 1Genentech, Inc., South San Francisco, California, USA
  2. 2Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California, San Francisco, California, USA
  1. Correspondence to Dr Joseph R Arron, Genentech, Inc., MS 34, 1 DNA Way, South San Francisco, CA 94080, USA; arron.joseph{at}gene.com

Abstract

Background Idiopathic pulmonary fibrosis (IPF) is associated with aberrant expression of developmental pathways, including Hedgehog (Hh). As Hh signalling contributes to multiple pro-fibrotic processes, Hh inhibition may represent a therapeutic option for IPF. However, no non-invasive biomarkers are available to monitor lung Hh activity.

Methods We assessed gene and protein expression in IPF and control lung biopsies, mouse lung, fibroblasts stimulated in vitro with sonic hedgehog (SHh), and plasma in IPF patients versus controls, and cancer patients before and after treatment with vismodegib, a Hh inhibitor.

Results Lung tissue from IPF patients exhibited significantly greater expression of Hh-related genes versus controls. The gene most significantly upregulated in both IPF lung biopsies and fibroblasts stimulated in vitro with SHh was CXCL14, which encodes a soluble secreted chemokine whose expression is inhibited in vitro by the addition of vismodegib. CXCL14 expression was induced by SHh overexpression in mouse lung. Circulating CXCL14 protein levels were significantly higher in plasma from IPF patients than controls. In cancer patients, circulating CXCL14 levels were significantly reduced upon vismodegib treatment.

Conclusions CXCL14 is a systemic biomarker that could be used to identify IPF patients with increased Hh pathway activity and monitor the pharmacodynamic effects of Hh antagonist therapy in IPF.

Trial registration number Post-results, NCT00968981.

  • Idiopathic pulmonary fibrosis

Statistics from Altmetric.com

Footnotes

  • Contributors GJ, SC, ARA, DJDeP, ENN, MBY, HMM, IP and JDeV designed, executed and analysed experiments. JGE and JRA conceived of and directed the studies. HRC and PJW enrolled IPF patients and collected samples. GJ, JGE and JRA wrote the manuscript. All authors reviewed and approved the content of the manuscript.

  • Funding Genentech, the Nina Ireland Program for Lung Health at UCSF, and NIH grant HL 108794.

  • Competing interests GJ, SC, ARA, DJDeP, ENN, MBY, HMM, IP, JDeV, JGE and JRA are or were employees of Genentech, Inc. when this work was conducted and may hold stock or stock options in the Roche Group. GJ, SC, ARA, DJDeP, JGE and JRA are named inventors on patents pending related to the diagnosis and treatment of pulmonary fibrosis.

  • Ethics approval UCSF Committee on Human Research.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.